{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:26:33Z","timestamp":1750829193600,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Council for Scientific and Technological Development \u2013 CNPq, Research Productivity","award":["304747\/2018-1","310135\/2022-2"],"award-info":[{"award-number":["304747\/2018-1","310135\/2022-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-023-04526-5","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T12:01:55Z","timestamp":1689854515000},"page":"2375-2380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette\u2013Gu\u00e9rin (BCG)"],"prefix":"10.1007","volume":"41","author":[{"given":"Danilo L.","family":"Andrade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrsa","family":"Jalalizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Clara C.","family":"Salustiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"Leonardo O.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"4526_CR1","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiology of bladder cancer. Med Sci (Basel) 8:15","journal-title":"Med Sci (Basel)"},{"key":"4526_CR2","unstructured":"C\u00e2ncer de bexiga (2022) Instituto Nacional de C\u00e2ncer. Updated July 18.\u00a0https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/tipos\/bexiga. Accessed Mar 2023"},{"key":"4526_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029","journal-title":"J Urol"},{"issue":"1","key":"4526_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran A, Cimadamore A, Blanca A et al (2021) Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel) 13(1):131","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4526_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00345-020-03294-w","volume":"39","author":"IGA Kiehl","year":"2021","unstructured":"Kiehl IGA, Riccetto E, Salustiano ACC et al (2021) Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-gu\u00e9rin association. World J Urol 39(4):1187\u20131194","journal-title":"World J Urol"},{"key":"4526_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12032-017-1067-2","volume":"35","author":"GR Passos","year":"2017","unstructured":"Passos GR, Camargo JA, Ferrari KL, Saad MJA, de Mattos AC, Reis LO (2017) Intravesical Thalidomide boosts bacillus Calmette\u2013Gu\u00e9rin (BCG) in non-muscle invasive bladder cancer treatment. Med Oncol 35:3","journal-title":"Med Oncol"},{"key":"4526_CR7","first-page":"3051","volume":"118","author":"CW Kinkade","year":"2008","unstructured":"Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al (2008) Targeting Akt\/Mtor and Erk Mapk signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118:3051\u20133064","journal-title":"J Clin Invest"},{"key":"4526_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525\u2013537","journal-title":"Ann Oncol"},{"key":"4526_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ (2017) Intravesical BCG induces CD4+ T cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res 5:594\u2013603","journal-title":"Cancer Immunol Res"},{"key":"4526_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.juro.2014.08.106","volume":"193","author":"KL Ferrari","year":"2015","unstructured":"Ferrari KL, de Camargo JA, Rocha GZ et al (2015) Intravesical bacillus Calmette\u2013Gu\u00e9rin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer. J Urol 193:682\u2013689","journal-title":"J Urol"},{"key":"4526_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/106689690501300203","volume":"13","author":"R Montironi","year":"2005","unstructured":"Montironi R, Lopez-Beltran A (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13:143\u2013153","journal-title":"Int J Surg Pathol"},{"key":"4526_CR12","unstructured":"(1993) Immunohistochemistry II: Edited by A. C. Cuello. IBRO handbook methods in the neurosciences, vol. 14. Wiley, Chichester, p 456"},{"issue":"5","key":"4526_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A (2014) IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE 9(5):e96801","journal-title":"PLoS ONE"},{"issue":"61","key":"4526_CR14","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.21105\/joss.03167","volume":"6","author":"I Patil","year":"2021","unstructured":"Patil I (2021) Visualizations with statistical details: the \u2018ggstatsplot\u2019 approach. J Open Source Softw 6(61):3167","journal-title":"J Open Source Softw"},{"key":"4526_CR15","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","volume":"39","author":"S Alanee","year":"2021","unstructured":"Alanee S, Sana S, El-Zawahry A et al (2021) Phase I trial of intravesical Bacillus Calmette\u2013Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette\u2013Gu\u00e9rin treatment. World J Urol 39:3807\u20133813","journal-title":"World J Urol"},{"key":"4526_CR16","doi-asserted-by":"publisher","first-page":"117955492110449","DOI":"10.1177\/11795549211044963","volume":"15","author":"LP Rhea","year":"2021","unstructured":"Rhea LP, Aragon-Ching JB (2021) Advances and controversies with checkpoint inhibitors in bladder cancer. Clin Med Insights Oncol 15:11795549211044964","journal-title":"Clin Med Insights Oncol"},{"key":"4526_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/biomedicines10020411","volume":"10","author":"BA Maiorano","year":"2022","unstructured":"Maiorano BA, De Giorgi U, Ciardiello D et al (2022) Immune-checkpoint inhibitors in advanced bladder cancer: seize the day. Biomedicines 10:411","journal-title":"Biomedicines"},{"key":"4526_CR18","unstructured":"ClinicalTrials.gov Identifier: NCT04375813. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04375813. Accessed Mar 2023"},{"key":"4526_CR19","first-page":"1069","volume":"28","author":"FM Aarestrup","year":"1995","unstructured":"Aarestrup FM, Gon\u00e7alves-da-Costa SC, Sarno EN (1995) The effect of thalidomide on BCG-induced granulomas in mice. Braz J Med Biol Res 28:1069\u20131076","journal-title":"Braz J Med Biol Res"},{"key":"4526_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106129","volume":"81","author":"BFM Castro","year":"2020","unstructured":"Castro BFM, Vieira LC, Vasconcelos-Santos DV et al (2020) Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. Int Immunopharmacol 81:106129","journal-title":"Int Immunopharmacol"},{"key":"4526_CR21","unstructured":"ClinicalTrials.gov identifier: NCT01373294. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01373294. Accessed Mar 2023"},{"key":"4526_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mrfmmm.2014.05.005","volume":"768","author":"N Di Santo","year":"2014","unstructured":"Di Santo N, Ehrisman J (2014) A functional perspective of nitazoxanide as a potential anticancer drug. Mutat Res 768:16\u201321","journal-title":"Mutat Res"},{"key":"4526_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114588","volume":"190","author":"H Sun","year":"2021","unstructured":"Sun H, Ou T, Hu J et al (2021) Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer. Biochem Pharmacol 190:114588","journal-title":"Biochem Pharmacol"},{"key":"4526_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3390\/biom11121817","volume":"11","author":"M Castillo-Salazar","year":"2021","unstructured":"Castillo-Salazar M, S\u00e1nchez-Mu\u00f1oz F, Springall Del Villar R et al (2021) Nitazoxanide exerts immunomodulatory effects on peripheral blood mononuclear cells from type 2 diabetes patients. Biomolecules 11:1817","journal-title":"Biomolecules"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04526-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:02:54Z","timestamp":1693342974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04526-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["4526"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04526-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved at University of Campinas Ethics Commitee on Animal Experimentation under numbers: 4540-1\/2017; 3163-1; and 3164-1.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}